Page 205 - Drug Class Review
P. 205

Drug Effectiveness Review Project










                                 donepezil      placebo   65%   70%   9%   20%   4%   10%   2%   9%   0%   9%   2%   8%   0%   6%   0%   5%     Significantly more donepezil patients experienced abnormal dreams (P = 0.03)   Post randomization exclusions: No   Overall loss to follow-up:  24%  Loss to follow-up differential high: No       placebo  donepezil      19%   27%   9%   16%         Page 133 of 205






                                                                            ITT: Yes   Method not reported      Method not reported   Yes       Fair





















             Final Report Update 1     Authors: Seltzer et al.   Year: 2004   ADVERSE EVENTS:   Overall adverse effects reported:   Diarrhea   •   Nausea   •   Asthenia   •   Abnormal Dreams   •   Dizziness   •   Injury   •   Insomnia   •  Significant differences in adverse   events:      ANALYSIS:    ADEQUATE RANDOMIZATION:   ADEQUATE ALLOCATION   CONCEALMENT:  BLINDING OF OUTCOME   ASSESSORS:   ATTRITION (overall):     ATTRITION (treatment specific):   Loss to follow-up:   Withdrawals due to adverse events:        QUALITY RATING:      *primary outcome measures     Alzheimer's Drugs
   200   201   202   203   204   205   206   207   208   209   210